Syncromune
Clinical-stage immuno-oncology — in-situ vaccination (SYNC-T) platform
Syncromune is a private biotech company that filed a SEC Form D on 2026-05-11 disclosing a $144.8M Regulation D offering. Officers and directors of record include Charles Link, Eamonn Hobbs, Joseph Gerardi, Agustin Gago, Joseph Maroon. Additional company details to be enriched from press and IR sources.
Biotech
Current Valuation
Private
PRIVATE
IPO Outlookprivate
Is Syncromune going public?
No. Syncromune is private and has not filed to go public. There is no S-1 on file.
What is Syncromune's valuation in 2026?
No confirmed valuation is on record for Syncromune. The roster shows funding and investors where they are public; it does not estimate a mark.
Has Syncromune filed an S-1?
No public S-1 is on file for Syncromune.
Who are Syncromune's investors?
Syncromune's investors include Joseph Maroon, Douglas Watson, Jeffrey Cleland, Norman Schwartz.
How much has Syncromune raised?
Syncromune has raised $144.83M in total, most recently a Form D filing of $144.83M in May 2026.
Is Syncromune publicly traded — can you buy Syncromune stock?
No. Syncromune is a private company — its shares are not listed on any exchange and there is no ticker. The routes to exposure are pre-IPO secondary marketplaces and funds (accredited investors), employee tender offers when the company runs one, and public companies with read-through exposure. QuantLogix maps every route it can verify for Syncromune on its Pre-IPO Access Desk.
Answers are derived from the roster record shown on this page — filing status, last round and confirmed marks. Where the record is silent, the answer says so rather than guessing.
Company Profile
Growth
Filed SEC Form D on 2026-05-11 for $144.8M Regulation D offering
Last Round
Form D filing — $144.83M (May 2026)
Fundraising Status
Form D filing · $144.83M · 5 mo ago
privateTotal raised $144.83M
Latest Funding Round
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Form D filing | $144.83M | May 2026 | — | — |
Vertical Intelligence — Biotech / Gene Therapy
Registered trials
1
1 active · 1 recruiting
Lead phase
Phase 2
most advanced registered study
Focus areas
Metastatic Castration-resistant Prostate Cancer
Latest trial start
2025-05-29
Talent Signal
No public careers page or job board could be found for Syncromune as of 2026-09-14. That itself is a datapoint: no open external hiring surface.
Checked the company site and major hosted job boards. Re-checked monthly.
Investors
Joseph Maroon · Douglas Watson · Jeffrey Cleland · Norman Schwartz
BiotechNew
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.